Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance

BioNTech SE - ADRTrade
Virgin Galactic Holdings, Inc.Trade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Virgin Galactic Holdings, Inc. — how do they compare? BioNTech SE - ADR trades at $90.53 (market cap $23.31B), while Virgin Galactic Holdings, Inc. trades at $3.34 (market cap $488.94M). The key difference: BioNTech SE - ADR is far larger — about 47.7× Virgin Galactic Holdings, Inc.'s market cap. Which is the better fit depends on your goals.

BNTXSPCE
Market Cap
$23.31B$488.94M
Sector
HealthIndustrials
52-Week High
$119.34$7.52
52-Week Low
$83.89$2.17
Enterprise Value
$6.60B$588.79M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.

Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.

Virgin Galactic Holdings, Inc.

SPCE trades at $3.10, up 5.8% in the last session, with a bullish technical signal from moving averages but an overbought RSI. The company continues to post significant losses, with a net income margin of -19,781.3% in 2025, though it has beaten EPS estimates for the last three quarters. Cash flow remains negative, but the trend is improving, with net cash flow narrowing to -$35.17 million in 2025 from -$207 million in 2022. Recent news highlights sector volatility and an upcoming Q2 2026 earnings report on August 12, 2026.

The outlook is highly speculative, with substantial execution risks and cash burn offset by potential in the nascent space tourism market. Analyst consensus is mixed, with 29% buy ratings. Investors face high volatility and operational challenges, making it suitable only for risk-tolerant portfolios seeking long-term growth in a disruptive industry.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Virgin Galactic Holdings, Inc.

Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.

Read more on SPCE